News | January 04, 2022
Combination of Covishield-Covaxin more effective: AIG hospital study
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It will be marketed under the brand name Molunamax
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Subscribe To Our Newsletter & Stay Updated
